Innovent Biologics (HK:1801)
:1801
Top Page
Innovent Biologics
(1801)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$83.00
▼(-9.29% Downside)
Action:ReiteratedDate:11/28/25
Innovent Biologics' strong revenue growth and solid balance sheet are overshadowed by its high P/E ratio and challenges in achieving profitability and positive cash flow. The technical indicators suggest positive momentum, but potential overvaluation and liquidity issues pose risks.
Positive Factors
Revenue Growth
Sustained high revenue growth demonstrates strong commercial traction for approved biologics and expanding market penetration in China. Durable top-line expansion can support scale economies, fund R&D and commercialization activities internally, and improve negotiating leverage with payers and partners.
Negative Factors
Negative Operating Cash Flow
Persistent negative operating cash flow limits the company’s ability to self-fund development and commercialization, forcing reliance on cash reserves or external financing. Over the medium term this can raise dilution risk, increase financing costs, and constrain strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth demonstrates strong commercial traction for approved biologics and expanding market penetration in China. Durable top-line expansion can support scale economies, fund R&D and commercialization activities internally, and improve negotiating leverage with payers and partners.
Read all positive factors
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$158.77B
Dividend YieldN/A
Average Volume (3M)16.11M
Price to Earnings (P/E)145.0
Beta (1Y)0.77
Revenue Growth52.78%
EPS GrowthN/A
CountryHK
Employees5,659
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,735,186,000
10 Day Avg. Volume15,175,046
30 Day Avg. Volume16,110,837
Financial Highlights & Ratios
PEG Ratio6.48
Price to Book (P/B)4.26
Price to Sales (P/S)5.94
P/FCF Ratio-133.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$117.08Price Target Upside27.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.4
Revenue Forecast (FY)HK$18.06B
Innovent Biologics Business Overview & Revenue Model
Company Description
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabo...
How the Company Makes Money
Innovent Biologics generates revenue primarily through the sale of its proprietary biologic products and collaborations with global pharmaceutical companies. Key revenue streams include product sales from its marketed therapies, licensing fees fro...
Innovent Biologics Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.42B | 9.42B | 6.21B | 4.56B | 4.27B | 3.84B |
| Gross Profit | 8.72B | 7.91B | 4.40B | 3.63B | 3.70B | 3.46B |
| EBITDA | 660.90M | -480.28M | -660.68M | -1.75B | -2.37B | -704.74M |
| Net Income | 1.13B | -94.63M | -1.03B | -2.18B | -2.73B | -998.42M |
Balance Sheet | ||||||
| Total Assets | 23.59B | 21.60B | 20.63B | 17.59B | 16.24B | 11.83B |
| Cash, Cash Equivalents and Short-Term Investments | 9.54B | 7.88B | 10.97B | 9.17B | 9.02B | 8.12B |
| Total Debt | 3.38B | 2.83B | 3.62B | 3.23B | 2.50B | 1.21B |
| Total Liabilities | 9.17B | 8.48B | 8.10B | 6.86B | 5.91B | 3.06B |
| Stockholders Equity | 14.42B | 13.12B | 12.53B | 10.73B | 10.33B | 8.78B |
Cash Flow | ||||||
| Free Cash Flow | 1.24B | -418.39M | -1.24B | -3.30B | -3.87B | -1.08B |
| Operating Cash Flow | 1.50B | 1.29B | 147.81M | -1.92B | -2.02B | -307.69M |
| Investing Cash Flow | -611.72M | -1.17B | -998.66M | -1.44B | -2.70B | -5.18B |
| Financing Cash Flow | -345.82M | -606.63M | 2.59B | 2.89B | 5.00B | 4.91B |
Innovent Biologics Technical Analysis
Positive
91.50
Price Trends
83.86
Positive
85.50
Positive
88.19
Positive
Market Momentum
1.05
Negative
61.68
Neutral
87.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1801, the sentiment is Positive. The current price of 91.5 is above the 20-day moving average (MA) of 83.67, above the 50-day MA of 83.86, and above the 200-day MA of 88.19, indicating a bullish trend. The MACD of 1.05 indicates Negative momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 87.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1801.
Innovent Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$64.41B | 9.63 | 14.85% | 0.95% | 7.51% | 44.09% | |
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
65 Neutral | HK$83.77B | 51.47 | 32.32% | ― | 46.14% | 39.56% | |
61 Neutral | HK$158.77B | 144.97 | 4.82% | ― | 52.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$129.42B | -84.52 | -14.40% | ― | 33.46% | -7.60% |
* Healthcare Sector Average
HK:1801
Innovent Biologics
91.50
51.85
130.77%
HK:1530
3SBio
25.38
15.34
152.81%
HK:9926
Akeso, Inc.
140.50
75.75
116.99%
HK:9995
RemeGen Co. Ltd. Class H
115.20
93.60
433.33%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
49.85
186.36%
Innovent Biologics Corporate Events
Innovent Surpasses RMB10 Billion in 2025 Product Revenue on Oncology and Chronic Disease Momentum
Feb 4, 2026
Innovent reported FY2025 product revenue of RMB11.9 billion, up 45% year over year, with fourth-quarter sales climbing over 60% to RMB3.3 billion thanks to six drugs entering the 2026 NRDL and sustained growth from flagship oncology br...
Innovent Wins Landmark China Approval for First Domestic CTLA-4 Neoadjuvant Colon Cancer Therapy
Dec 28, 2025
Innovent Biologics announced that China’s National Medical Products Administration has approved its CTLA-4 monoclonal antibody TABOSUN (ipilimumab N01 injection) in combination with its PD-1 inhibitor sintilimab as a neoadjuvant treatment fo...
Innovent Biologics’ Seven Drugs Added to China’s National Reimbursement List
Dec 7, 2025
Innovent Biologics has announced the inclusion of seven innovative drugs in China’s updated 2025 National Reimbursement Drug List (NRDL), which will be effective from January 1, 2026. This inclusion covers key disease areas such as oncology ...
Innovent Biologics Grants Share Options to Boost Employee Engagement
Dec 5, 2025
Innovent Biologics announced the grant of 15,000 share options and 148,200 restricted shares to non-connected employees as part of its 2024 Share Scheme. This move is designed to incentivize employees by aligning their interests with company perfo...
Innovent Biologics Closes Strategic Partnership with Takeda
Dec 4, 2025
Innovent Biologics, Inc. has successfully closed a global strategic partnership with Takeda, fulfilling all conditions of their License, Option, and Collaboration Agreement, as well as the Share Issuance Agreement. This resulted in the issuance of...
Innovent Biologics’ PECONDLE® Approved for Psoriasis Treatment in China
Nov 28, 2025
Innovent Biologics has announced that its new drug, PECONDLE® (picankibart injection), has received approval from China’s National Medical Products Administration for treating moderate-to-severe plaque psoriasis. This approval marks the...
Innovent’s Mazdutide 9mg Application Accepted by China’s NMPA
Nov 25, 2025
Innovent Biologics has announced that China’s National Medical Products Administration has accepted the supplementary application for the 9mg dosage of mazdutide, a dual receptor agonist for weight management in adults with moderate to sever...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.